Language

CAS No.13647-35-3 | Trilostane

Name: Trilostane CAS No.13647-35-3 MF:C20H27NO3 MW:329.43 Purity:98% Package: 10g,25g,50g,100g,250g Worldwide Delivery

Categories：

Biochemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 13647-35-3 | Trilostane

Synonyms:TRILOSTANE;

(2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-car;

17-beta)-ph;

(4a,5a,17b)-3,17-Dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile;

5a-Androstane-2a-carbonitrile,4a,5-epoxy-17b-hydroxy-3-oxo-;

Androst-2-ene-2-carbonitrile,4,5-epoxy-3,17-dihydroxy-,(4a,5a,17b)-;

4α,5-Epoxy-3,17β-dihydroxy-5α-androst-2-ene-2-carbonitrile;

4α,5-Epoxy-3,17β-dihydroxy-5α-androstan-2-ene-2-carbonitrile

Specification:

ITEMS	SPECIFICATION
CAS	13647-35-3
MF	C20H27NO3
MW	329.43
Melting point	264 °C
Boiling point	467.02°C
Density	1.1213
Acidity coefficient	8.57±0.70
Color	white to tan
Solubility	Solubility in DMSO ≥17mg/mL
Form	Powder
Storage condition	2-8°C

Indications:

Trilostane can inhibit 3β-dehydrogenase in the synthesis process of corticosteroids, reducing the synthesis of cortisol and aldosterone. It is clinically used to treat Cushing's syndrome (hypercortisolism) and primary aldosteronism, but the therapeutic pool Hin syndrome (hypercortisolism) is less effective than metyrapone. This product also has a significant effect on reducing blood testosterone levels, which may be related to inhibiting its synthesis.

Mechanism:

Breast cancer is a hormone-dependent tumor, and estrogen is the main driver of cancer cell growth. Therefore, one of the main modern treatments for breast cancer is to target estrogen, either by inhibiting estrogen production or blocking the effects of estrogen at its site of action, the estrogen receptor link. It was originally thought that the estrogen receptor was a single receptor, but recent studies have identified that it has at least two subtypes, alpha and beta. Estrogen can stimulate cell growth after binding to α-estrogen receptors, but binding to β-estrogen receptors will downregulate α-estrogen receptors and slow down cell proliferation. Research has revealed that in addition to reducing the production of estrogen, trilostane can also regulate the binding of estrogen to different subtypes of estrogen receptors, and simultaneously acts as an α-estrogen receptor inhibitor and a β-estrogen receptor agonist. The dual effect ultimately blocks and changes the negative impact of estrogen on cancer cells. Trilostane's unique mode of action not only distinguishes it from other existing anti-estrogen drugs, but also is the pharmacological basis for its high efficacy in breast cancer that has failed or is resistant to other anti-estrogen therapies.

Package and transportation :

Package: 10g,25g,50g,100g,250g